The M918V mutation has been shown to have low oncogenic potential by in vitro testing [50] and has been associated with a moderate risk of MTC in a recent study of multiple families, none of whom presented clinical features of MEN2B [16, 51]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.